Humalog has a very rapid onset of action, allowing it to be given immediately before a meal, compared to regular insulin, which should be given 30 minutes before a meal. In initial clinical pharmacology studies, the onset of action of Humalog was seen within 15 minutes of administration, whil...
Insulin, including HUMALOG Mix75/25, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Weight Gain Weight gain can occur with insulin therapy, including HUMALOG Mix75/25, and has been attributed to the anabolic effects...
ADMELOG (insulinlispro injection) is a rapid-acting human insulinanalogused to lowerblood glucose. Insulin lispro is produced byrecombinant DNA technologyutilizing a non-pathogeniclaboratory strain ofEscherichia coli. Insulin lispro differs from human insulin in that theamino acidproline at position B28...
Simpson D, McCormack PL, Keating GM, et al. Insulin lispro: a review of its use in the management of diabetes mellitus. Drugs 2007; 67(3): 407–34Simpson D, McCormack PL, Keating GM, Lyseng-Williamson KA. Insulin lispro: a review of its use in the management of diabetes mellitus. ...
insulin analogue, has a quick 5–15 min onset of action and peaks in 30–90 min with an effective duration of only 4–6 h (Hirsch, 2005a). This type of insulin was designed to treat diabetics enjoying a food bolus. The resulting peak in endogenous insulin ...
OBJECTIVE — Insulin lispro (Humalog), a human insulin analog, has a more rapid onset, earlier peak, and shorter duration of glucose lowering activity than regular human insulin. However, it is not known whether insulin lispro crosses the human placenta and reaches the fetus. Therefore, the ...